XBIO
Xenetic Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.93
−3.02%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.93
From 52W high−58.67%
Volume10118.00
Market cap$4.52M
P/E (TTM)—
P/S (TTM)1.4x
Div yield—
Key dataOct 19, 2026
Open
$1.93
From 52W high
−58.67%
Volume
10118.00
Market cap
$4.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
P/E (TTM)
—
RSI (14)
28.8
MomentumView details →
1D Return
−3.02%
YTD Return
−14.75%
SummaryUpdated Jun 1, 2026
Xenetic Biosciences, Inc. (NASDAQ:XBIO) is a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Framingham, Massachusetts. The company went public in 2016 and focuses on developing innovative cancer treatments through its proprietary cell therapy platform and drug delivery technologies. Xenetic operates as a research and development-focused biotech company, advancing personalized cancer therapies while also leveraging its drug delivery platform through strategic partnerships with larger pharmaceutical companies.
Similar companies
Latest newsMore news →
Xenetic Biosciences signed a Share Exchange Agreement to acquire all issued share capital of Santersus AG, with Santersus shareholders expected to hold about 85% of the combined company, which will be renamed Santersus Bio, Inc.34d agoXenetic Biosciences reported financial results for the quarter ended June 30, 2026, and provided a corporate update on its DNase platform development strategy.74d ago